Citadel Advisors
LUMO

Citadel Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Citadel Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,756
Closed -$86K – 10329
2019
Q4 		$86K Buy
3,756
+156
+4% +$2.23K ﹤0.01% 8600
2019
Q3 		$52K Buy
+3,600
New +$52.8K ﹤0.01% 8691
2019
Q2 		– Sell
-2,122
Closed -$37K – 10003
2019
Q1 		$37K Buy
2,122
+989
+87% +$14.7K ﹤0.01% 8936
2018
Q4 		$16K Sell
1,133
-3,589
-76% -$63.2K ﹤0.01% 8823
2018
Q3 		$102K Sell
4,722
-3,034
-39% -$92.3K ﹤0.01% 8574
2018
Q2 		$332K Buy
7,756
+3,656
+89% +$167K ﹤0.01% 7043
2018
Q1 		$268K Sell
4,100
-1,311
-24% -$92.9K ﹤0.01% 6915
2017
Q4 		$395K Buy
5,411
+767
+17% +$63.4K ﹤0.01% 6029
2017
Q3 		$426K Buy
4,644
+2,022
+77% +$155K ﹤0.01% 5556
2017
Q2 		$173K Sell
2,622
-122
-4% -$15.1K ﹤0.01% 6648
2017
Q1 		$595K Buy
2,744
+1,444
+111% +$206K ﹤0.01% 4749
2016
Q4 		$120K Sell
1,300
-933
-42% -$105K ﹤0.01% 6605
2016
Q3 		$302K Sell
2,233
-1,611
-42% -$160K ﹤0.01% 5663
2016
Q2 		$390K Buy
3,844
+1,533
+66% +$190K ﹤0.01% 4830
2016
Q1 		$379K Buy
2,311
+667
+41% +$135K ﹤0.01% 4794
2015
Q4 		$539K Sell
1,644
-1,156
-41% -$376K ﹤0.01% 4376
2015
Q3 		$903K Buy
2,800
+156
+6% +$68.5K ﹤0.01% 3953
2015
Q2 		$1.05M Sell
2,644
-6,400
-71% -$2.72M ﹤0.01% 3906
2015
Q1 		$4.45M Buy
9,044
+4,066
+82% +$1.58M ﹤0.01% 2147
2014
Q4 		$1.78M Buy
4,978
+578
+13% +$172K ﹤0.01% 3047
2014
Q3 		$848K Buy
4,400
+1,278
+41% +$281K ﹤0.01% 3915
2014
Q2 		$746K Sell
3,122
-2,367
-43% -$481K ﹤0.01% 3873
2014
Q1 		$1.4M Buy
5,489
+1,211
+28% +$370K ﹤0.01% 3002
2013
Q4 		$847K Sell
4,278
-211
-5% -$37.5K ﹤0.01% 3390
2013
Q3 		$759K Buy
+4,489
New +$723K ﹤0.01% 3380

Other funds holding LUMO

PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Citadel Advisors's LUMO Position: Q3 2024 in Review

Citadel Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2024, closing a stake of 18,745 shares — an estimated $43.5K sold.

Citadel Advisors first reported a position in LUMO in Q4 2013 and held it in 26 quarters. The position peaked at $5.26M in Q1 2015. 28 funds tracked by Wall St. Rank hold LUMO as of Q3 2024.

  • Citadel Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 18,745 Lumos Pharma, Inc. Common Stock shares in Q3 2024, an estimated $43.5K.
  • Citadel Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 26 quarters.
  • Citadel Advisors's Lumos Pharma, Inc. Common Stock position peaked at $5.26M in Q1 2015.
  • 28 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.